Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
10,001 - 25,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
5,001 - 15,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 10 epsHost
Recent guests
Recent episodes
Approaching MDS: Advances in Diagnostics, Therapeutics and Monitoring
Apr 16, 2026
25m 27s
New Horizons in Smoldering Multiple Myeloma
Mar 19, 2026
26m 19s
Interpreting Abnormal SPEP – Is It Just MGUS?
Feb 19, 2026
27m 10s
Sticky Situations: The Role of Thrombophilia Testing in VTE Management
Jan 15, 2026
28m 03s
Lost in Translation: The aHUS Experience
Dec 18, 2025
20m 15s
Social Links & Contact
Official channels & resources
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 4/16/26 | ![]() Approaching MDS: Advances in Diagnostics, Therapeutics and Monitoring✨ | myelodysplastic neoplasmsdiagnostics+4 | Dr. DeZernDr. Mack | American Society of Hematologymyelodysplastic neoplasms+1 | — | MDSdiagnosis+6 | — | 25m 27s | |
| 3/19/26 | ![]() New Horizons in Smoldering Multiple Myeloma✨ | smoldering multiple myelomatreatment landscape+3 | Brea LipeSagar Lonial | American Society of Hematology | United States | smoldering multiple myelomaMGUS+4 | — | 26m 19s | |
| 2/19/26 | ![]() Interpreting Abnormal SPEP – Is It Just MGUS?✨ | MGUSserum protein electrophoresis+3 | Rahma WarsameJason Chen | American Society of HematologyInterpreting Abnormal SPEP – Is It Just MGUS? | — | MGUSserum monoclonal protein+3 | — | 27m 10s | |
| 1/15/26 | ![]() Sticky Situations: The Role of Thrombophilia Testing in VTE Management✨ | thrombophilia testingVTE management+3 | Ronak MistryJori May | American Society of Hematology | — | thrombophiliaVTE+3 | — | 28m 03s | |
| 12/18/25 | ![]() Lost in Translation: The aHUS Experience✨ | aHUSpatient advocacy+3 | Dr. Toyosi Onwuemene | aHUS FoundationAmerican Society of Hematology | — | aHUShemolytic uremic syndrome+5 | — | 20m 15s | |
| 11/20/25 | ![]() Inclusion of those with those with Duffy-null Associated Neutrophil Count (DANC) in Clinical Trials✨ | Duffy null phenotypeabsolute neutrophil count+4 | Dr. Andrew HintelDr. Lauren Merz | American Society of HematologyDoris Duke Foundation | — | Duffy-nullneutrophil count+4 | — | 25m 50s | |
| 10/16/25 | ![]() Thalassemia in Pediatric Hematology✨ | thalassemiapediatric hematology+4 | Sujit ShethAshutosh Lal | American Society of Hematologybeta-thalassemia major | MediterraneanMiddle East+2 | thalassemiapediatric+6 | — | 19m 21s | |
| 9/18/25 | ![]() Bridging the Gap: Coordinating CAR-T Care Between Community and Academic Practices✨ | CAR-T therapycare coordination+4 | Dr. CaimiDr. Sdrimas | American Society of Hematology | — | CAR-Tpatient care+6 | — | 20m 00s | |
| 8/21/25 | ![]() Relapsed Myeloma: Navigating Post-BCMA Therapy Failure✨ | relapsed myelomaBCMA therapy failure+4 | Dr. Natalia NeparidzeDr. Saad Z. Usmani | CAR T-cell therapybispecific antibodies+2 | BCMAmultiple myeloma | relapsed myelomaBCMA-targeted therapy+4 | — | 22m 46s | |
| 7/17/25 | ![]() Hereditary Hemorrhagic Telangiectasia: Diagnosis, Management, and Advances✨ | hereditary hemorrhagic telangiectasiadiagnosis+4 | Hanny Al-SamkariAdrienne Hammill | American Society of Hematology | — | HHTtelangiectasia+5 | — | 22m 38s | |
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 6/19/25 | ![]() Thrombotic Microangiopathy in Pregnancy: Challenges and Advances | Join us for an insightful discussion on thrombotic microangiopathy (TMA) in pregnancy with Drs. Richard Burwick and Shruti Chaturvedi as we navigate the complexities of diagnosing and managing hypertensive disorders in pregnancy. These conditions often present overlapping clinical and laboratory features, making timely and accurate intervention challenging. Through the case of a 32-year-old woman at 30 weeks' gestation with severe hypertension, headache, and new-onset thrombocytopenia, we will explore key diagnostic considerations, the distinguishing features of preeclampsia with severe features, Hemolysis, Elevated Liver enzymes, and Low Platelets (HELLP) syndrome, and TMA, and the best strategies for optimizing maternal and fetal outcomes in these high-risk situations. This episode offers practical, evidence-based insights to enhance the recognition and management of pregnancy-related TMA and hypertensive disorders. Learning Objectives: Differentiate between preeclampsia with severe features, HELLP syndrome, and TMA using clinical and laboratory findings. Identify the most appropriate diagnostic tests to confirm the underlying etiology in pregnant patients with hypertension and thrombocytopenia. Discuss immediate and long-term management strategies, including when to initiate delivery and the role of plasma exchange in suspected TMA. | 25m 06s | ||||||
| 5/15/25 | ![]() Unveiling Von Willebrand Disease: Advances in Diagnosis and Treatment | In this episode of HemeTalks, Dr. Jill Johnsen and Dr. Michelle Sholzberg explore Von Willebrand Disease (VWD), the most common inherited bleeding disorder. The discussion delves into the disease's pathophysiology, diagnostic challenges, and the latest advancements in treatment. Learn about the complexities of diagnosing VWD, and discover we are working together to improve outcomes. This episode provides valuable insights for hematologists and healthcare professionals involved in the management of bleeding disorders. Learning Objectives: Understand the different ways that Von Willebrand Disease can present. Identify the challenges and best practices for diagnosing Von Willebrand Disease. Understand treatment options for Von Willebrand Disease and importance of personalized care. | 20m 58s | ||||||
| 4/17/25 | ![]() Battling Invisible Enemies: Toxic Exposures and Hematologic Cancers in Military Members | Join us on HemeTalks as Dr. Christin DeStefano and Dr. Drew Helmer discuss the impact of military toxic exposures on the development of hematologic malignancies, including leukemia, lymphoma, and myeloma. Learn about the challenges of diagnosing and treating these cancers, advancements in research, and strategies for improving care for military members and veterans. Learning Objectives:Discuss challenges in studying the effects of toxic exposures commonly experienced during military service and their links to hematologic cancers. Understand the unique evaluation and treatment challenges for hematologic malignancies in veterans and active-duty military members. Explore hematology-specific research and initiatives aimed at improving early detection and care for this population. | 21m 33s | ||||||
| 3/13/25 | ![]() Iron-Clad Health: Tackling Iron Deficiency in Women | Dr. Anjlee Mahajan (@anjleemd), Dr. Angela Weyand (@acweyand) and Dr. Michelle Sholzberg (@sholzberg ) delve into how current standards of care may contribute to disparities in the diagnosis and treatment of iron deficiency, particularly among female patients, as well as sharing compelling valuable insights into important considerations in addressing and overcoming these challenges to advance quality of care and improved outcomes for patients.Learning Objectives: To educate hematologists and coordinating healthcare providers, where possible, on…Some health inequities and challenges in providing comprehensive care to women with iron deficiency,Examples of identifying and treating patients with iron deficiency, andPractical steps we can all take to improve care of patients with iron deficiency. | 21m 08s | ||||||
| 2/13/25 | ![]() The Road to Inclusion: Navigating Challenges to Haploidentical Donor Transplants | Dr. Shakira Grant and Dr. Irum Kahn explore the fascinating history of stem cell transplants, beginning with its origins and milestones in the field such as the evolution of haploidentical transplants, a groundbreaking approach that has expanded donor options and improved outcomes for patients from diverse backgrounds. They then examine the clinical implications of these advancements, their transformative impact on patient care, and the power of diversity in donation.Learning Objectives: To educate hematologists on…Key barriers patients face in accessing stem cell transplantation, including financial, racial-ethnic, and logistical challenges,The importance of racial and ethnic diversity in stem cell donor registries and the steps being taken to improve it, andPolicy-level solutions and interventions aimed at reducing cost barriers for patients needing stem cell transplantation. | 21m 32s | ||||||
| 1/16/25 | ![]() Blood for All: Clinical Impacts of Diverse Donor Pools | Dr. Rahma Warsame (@RWarsameMD) sits down with Dr. Margo Rollins to explore the critical clinical importance of diverse blood donors and unique challenges faced in recruiting and retaining a diverse donor pool. They then delve into practical strategies and opportunities to overcome these barriers. Join us to gain valuable insights into how enhancing donor diversity can significantly improve patient outcomes and promote health equity. Learning Objectives: To educate hematologists on…The importance of donor diversity in blood donations.Challenges faced in recruiting and retaining a diverse pool particularly from BIPOC communities.Strategies toward overcoming these barriers. | 20m 44s | ||||||
| 12/19/24 | ![]() Advancing Sickle Cell Disease Care: A conversation between cellular therapy & BMT providers | Are you a healthcare professional seeking clarity on the evolving treatments for sickle cell disease (SCD)? In this 20-minute episode, experts from cellular therapy and bone marrow transplantation (BMT) explore key updates in SCD care, including curative therapies, gene-editing innovations, and BMT approaches. They address practical challenges in integrating these treatments into practice and discuss strategies to improve access and outcomes. Tune in to discover how collaboration between cellular therapy and BMT providers is transforming care and paving the way for better patient experiences. Learning Objectives Understand recent advancements in curative therapies, including gene editing and BMT, for sickle cell disease. Identify key challenges and barriers to integrating new treatments into clinical practice for SCD patients. Explore collaborative care strategies between cellular therapy and BMT providers to improve patient outcomes and access. | 20m 42s | ||||||
| 11/21/24 | ![]() Inside ASH 2024: Insights from the Education Program Co-Chairs | Join us for an insightful podcast episode featuring the Co-Chairs of the upcoming 2024 ASH Annual Meeting, where we explore the planning process and strategic goals that shaped this year’s program. Discover how the Co-Chairs ensured the Education Program meets the diverse needs of the hematology community, and the unique challenges faced during the planning and how they were overcome. Gain exclusive insights into what makes this event the premier gathering for professionals in the field. Whether attending in person or virtually, find out how you can maximize your experience and apply the latest advancements to your practice or research.Learning Objectives:Understand the Planning Process: Learn about the strategic goals, collaborative efforts, and decision-making that guided the design of the Education Program for the 66th ASH Annual Meeting, ensuring it addresses the diverse needs of the hematology community.Overcome Planning Challenges: Learn about the specific challenges encountered during the planning of this year’s program and how they were effectively managed to deliver a meaningful experience for attendees.Impact on Practice and Research: Understand how this year’s program is designed to impact attendees' practices and research, fostering advancements in the field of hematology. | 16m 06s | ||||||
| 10/24/24 | ![]() Blood Transfusion Safety: TRALI vs TACO | Join us as we explore blood transfusion safety, focusing specifically on Transfusion-Related Acute Lung Injury (TRALI) and Transfusion-Associated Circulatory Overload (TACO). Tailored for general hematologists with a foundational understanding of transfusion medicine, this session delves into the pathophysiology, clinical presentation, diagnostic criteria, and management strategies for TRALI and TACO. Through advanced discussions, participants will deepen their knowledge of these complications, enabling them to recognize, diagnose, and manage TRALI and TACO effectively in clinical practice.Learning Objectives:Gain a thorough understanding of the pathophysiology and clinical presentation of TRALI and TACO.Familiarize with the diagnostic criteria and differential diagnosis of TRALI and TACO.Develop effective management strategies for TRALI and TACO to ensure transfusion safety and enhance patient outcomes. | 20m 03s | ||||||
| 9/12/24 | ![]() Advancing Sickle Cell Disease Care: Navigating Gene Therapy | Are you a hematologist or a generalist provider seeking clarity on how to best counsel patients with sickle cell disease (SCD) who are interested in gene therapy? Join us for a podcast session focused on important patient considerations for gene therapy, tailored for SCD providers and clinicians. This session aims to provide practical insights to facilitate clear communication between providers, patients with SCD, and their families about treatment options.Learning ObjectivesUnderstand the Basics of Gene Therapy Treatments & SCD: By the end of the podcast, listeners will be able to identify some basic tenants of transformative treatments for sickle cell disease (SCD), focusing on how gene therapy treatments compare to other disease modifying treatments.Counseling Patients and Families: Listeners will be given suggestions on what key information to provide to patients and families that are interested in gene therapies, especially considering the build-up to gene therapy and also potential long-term effects.Enhance Communication Skills: This episode will suggest effective communication strategies to provide patients with both perspective and empathy while discussing gene therapy and other treatment options. | 17m 11s | ||||||
| 8/22/24 | ![]() Updates in Thalassemia: New Challenges and Novel Treatment Approaches | Speakers: Alexis Thompson, MD, and Sujit Sheth, MDDescription:For general hematologists with a foundational understanding of thalassemia, this episode discusses the changing demographics due to immigration and refugee resettlement. It covers the diagnosis process from newborn screening to older individuals, emphasizing genetic testing due to numerous mutations and varied phenotypes. The importance of correctly diagnosing older individuals previously misdiagnosed with iron deficiency refractory to treatment is highlighted. The episode also addresses regular transfusions, iron chelation, and monitoring for complications, along with advances in blood supply safety, reduced alloimmunization risks through extended typing, and MRI monitoring. Finally, novel agents in practice and development, including luspatercept, PK activators, and gene therapy, will be explored. Learning Objectives:Understand the changing landscape of thalassemia in the US. Revisit the state-of-the-art diagnostic and treatment approaches. Learn about novel therapeutics in the thalassemia field. | 20m 19s | ||||||
| 1/31/24 | ![]() Multiple Myeloma in Underrepresented Populations: Treatment Considerations | Dr. Azam Farooqui (@azamfarooqui ) and Dr. Monique Hartley-Brown (@DrMHB1) discuss therapeutic considerations regarding current and emerging agents for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License. | 24m 04s | ||||||
| 1/31/24 | ![]() Multiple Myeloma in Underrepresented Populations: Survival Outcomes | Dr. Azam Farooqui (@azamfarooqui )and Dr. Sikander Ailawadhi answer the question: Why do we need earlier diagnosis and intervention in patients with multiple myeloma from underrepresented racial and ethnic groups? Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License. | 18m 54s | ||||||
| 1/31/24 | ![]() Multiple Myeloma in Underrepresented Populations: Clinical Risk | Dr. Azam Farooqui (@azamfarooqui) and Dr. Urvi Shah (@UrviShahMD) identify factors that impact outcomes for patients with multiple myeloma from underrepresented racial and ethnic groups. Coming Soon!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: “Happy Medium” Zac Nelson (shutterstock.com). Licensed under Shutterstock: Standard License. | 16m 42s | ||||||
| 1/31/24 | ![]() IMPACT II: Impacting Multiple Myeloma in All CommuniTies | Season 2: IMPACT II: Impacting Multiple Myeloma in All CommuniTiesUnlock insights into the treatment of multiple myeloma within underrepresented racial and ethnic populations with this series of three enlightening podcast episodes. Join experts from both academic and community oncology settings as they dive into critical aspects of clinical risk, survival outcomes, and treatment considerations.Episode 1: Uncover the factors influencing outcomes for multiple myeloma patients from underrepresented racial and ethnic groups with Dr. Shah.Episode 2: Join Dr. Ailawadhi in exploring a hypothetical scenario of equal conditions and envision how mortality and survival outcomes may differ for multiple myeloma patients from underrepresented groups. Episode 3: Gain valuable insights from Dr. Hartley-Brown as she discusses therapeutic considerations for both current and emerging agents tailored to multiple myeloma patients from underrepresented racial and ethnic backgrounds.Are you ready to expand your understanding of multiple myeloma treatment disparities? Listen to Season 2 of HemeTalks on Apple Podcasts, Spotify, Google Podcasts, or your preferred podcast platform! Don't forget to bookmark the ASH Podcast webpage for easy access.Coming Soon ASH Academy On Demand!Prepare to enhance your knowledge through the IMPACT II online learning module on ASH Academy On Demand! Participants will develop an increased ability to identify variations in factors influencing mortality and survival outcomes among individuals from racial and ethnic minority groups with multiple myeloma.Music: "PeriTune - Investigation2(Suspense-Royalty Free Music)" by PeriTune is licensed under CC BY 3.0. | 1m 33s | ||||||
Showing 25 of 32
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
16 placements across 16 markets.
Chart Positions
16 placements across 16 markets.


























